Humacyte, Inc. (HUMA) News

Humacyte, Inc. (HUMA): $4.33

0.03 (+0.70%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add HUMA to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#331 of 357

in industry

Filter HUMA News Items

HUMA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HUMA News Highlights

  • HUMA's 30 day story count now stands at 2.
  • Over the past 18 days, the trend for HUMA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about HUMA are DEC and NOV.

Latest HUMA News From Around the Web

Below are the latest news stories about HUMACYTE INC that investors may wish to consider to help them evaluate HUMA as an investment opportunity.

Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma

– BLA supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime trauma injuries in Ukraine – – The HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks – DURHAM, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissu

Yahoo | December 12, 2023

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will present at the Piper Sandler 35th Annual Healthcare Conference, in New York, NY on November 30, 2023. Management will also be available for one

Yahoo | November 24, 2023

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

– Presentations included results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime injuries in Ukraine – – Results showed the HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks – – BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter – DURHAM, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasda

Yahoo | November 17, 2023

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November ...

Yahoo | November 14, 2023

Humacyte Third Quarter 2023 Financial Results and Business Update

– Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair – – BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter – - Conference call and live webcast at 4:30 p.m. ET today - DURHAM, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, t

Yahoo | November 9, 2023

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023. Management will host a webcast and conference call at 4:30 p.m. ET to provide a corporate and financial update. Title:Humacyte Third Quarter 2023 Earnings Conference CallDate:

Yahoo | November 2, 2023

Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model

-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease-DURHAM, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced publication of a preclinical study showing the potential for its investigational small-diameter Human Acellular Vessel™ (HAV™) to treat Tetralogy of Fallot, a heart condition that affects one

Yahoo | October 16, 2023

Several Insiders Invested In Humacyte Flagging Positive News

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | October 2, 2023

'Politicians have too much power': Sen. Tommy Tuberville recently disclosed $250K in agriculture futures — all while he's been influencing farming industry policies

And that's not the senator's only recent profitable trade that's drawing attention.

Yahoo | September 23, 2023

Humacyte to Present at the Cantor Global Healthcare Conference

DURHAM, N.C., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will present at the Cantor Global Healthcare Conference, in New York, NY on September 28, 2023. Management will also be available for one-on-one me

Yahoo | September 21, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!